Cargando…

Novel approaches to treating advanced systemic mastocytosis

Mastocytosis is a myeloproliferative neoplasm characterized by expansion of abnormal mast cells (MCs) in various tissues, including skin, bone marrow, gastrointestinal tract, liver, spleen, or lymph nodes. Subtypes include indolent systemic mastocytosis, smoldering systemic mastocytosis and advanced...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gilreath, JA, Tchertanov, L, Deininger, MW
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6630092/ https://www.ncbi.nlm.nih.gov/pubmed/31372066 http://dx.doi.org/10.2147/CPAA.S206615

Ejemplares similares

Efficacy and safety of avapritinib in previously treated patients with advanced systemic mastocytosis
por: Reiter, Andreas, et al.
Publicado: (2022)

Systemic Mastocytosis: Multidisciplinary Approach
por: Zanotti, Roberta, et al.
Publicado: (2021)

Treatment of Indolent and Advanced Systemic Mastocytosis
por: Buonomo, Alessandro, et al.
Publicado: (2022)

Clinical potential of midostaurin in advanced systemic mastocytosis
por: Chandesris, Marie Olivia, et al.
Publicado: (2017)

Recent advances in diagnosis and therapy in systemic mastocytosis
por: Lee, Hyun Jung
Publicado: (2023)

Antibody-Based and Cell Therapies for Advanced Mastocytosis: Established and Novel Concepts
por: Valent, Peter, et al.
Publicado: (2023)

Precision Medicine in Systemic Mastocytosis
por: Nicolosi, Maura, et al.
Publicado: (2021)

Preclinical human models and emerging therapeutics for advanced systemic mastocytosis
por: Arock, Michel, et al.
Publicado: (2018)

Gastrointestinal Manifestations in Systemic Mastocytosis: The Need of a Multidisciplinary Approach
por: Zanelli, Magda, et al.
Publicado: (2021)

Safety and efficacy of avapritinib in advanced systemic mastocytosis: the phase 1 EXPLORER trial
por: DeAngelo, Daniel J., et al.
Publicado: (2021)

Recent advances in the understanding and therapeutic management of mastocytosis
por: Rossignol, Julien, et al.
Publicado: (2019)

Response Criteria in Advanced Systemic Mastocytosis: Evolution in the Era of KIT Inhibitors
por: Shomali, William, et al.
Publicado: (2021)

Advanced systemic mastocytosis: the impact of KIT mutations in diagnosis, treatment, and progression
por: Verstovsek, Srdan
Publicado: (2013)

New Insights into the Pathogenesis of Systemic Mastocytosis
por: Li, Zhixiong
Publicado: (2021)

Target Therapies for Systemic Mastocytosis: An Update
por: Sciumè, Mariarita, et al.
Publicado: (2022)

Recent Advances in the Molecular Biology of Systemic Mastocytosis: Implications for Diagnosis, Prognosis, and Therapy
por: Martelli, Margherita, et al.
Publicado: (2020)

P1027: RESPONSES TO AVAPRITINIB IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS: HISTOPATHOLOGIC ANALYSES FROM EXPLORER AND PATHFINDER CLINICAL STUDIES
por: George, T., et al.
Publicado: (2022)

Systemic Mastocytosis: Radiological Point of View
por: Leone, Antonio, et al.
Publicado: (2021)

Catching the clinical and biological diversity for an appropriate therapeutic approach in systemic mastocytosis
por: Mannelli, Francesco
Publicado: (2020)

Melanoma and Mastocytosis
por: Vojvodic, Aleksandra, et al.
Publicado: (2019)

Treatment of Advanced Systemic Mastocytosis with Midostaurin: Practical Guidance for Optimal Therapy and Management
por: Papayannidis, Cristina, et al.
Publicado: (2022)

Efficacy and safety of avapritinib in advanced systemic mastocytosis: interim analysis of the phase 2 PATHFINDER trial
por: Gotlib, Jason, et al.
Publicado: (2021)

FDA Approval Summary: Midostaurin for the Treatment of Advanced Systemic Mastocytosis
por: Kasamon, Yvette L., et al.
Publicado: (2018)

Pregnancy and Delivery in Patients with Mastocytosis Treated at the Polish Center of the European Competence Network on Mastocytosis (ECNM)
por: Ciach, Katarzyna, et al.
Publicado: (2016)

MARS: Mutation-Adjusted Risk Score for Advanced Systemic Mastocytosis
por: Jawhar, Mohamad, et al.
Publicado: (2019)

The Efficacy of Cladribine (2-CdA) in Advanced Systemic Mastocytosis
por: Helbig, Grzegorz, et al.
Publicado: (2020)

Systemic Mastocytosis: Molecular Landscape and Implications for Treatment
por: Monaldi, Cecilia, et al.
Publicado: (2021)

Pediatric Mastocytosis: An Update
por: Giona, Fiorina
Publicado: (2021)

Cutaneous mastocytosis in childhood
por: Nemat, Katja, et al.
Publicado: (2022)

Multidisciplinary Challenges in Mastocytosis and How to Address with Personalized Medicine Approaches
por: Valent, Peter, et al.
Publicado: (2019)

An elusive case of systemic mastocytosis
por: Lee, JK, et al.
Publicado: (2010)

Systemic Lymphadenopathic Mastocytosis with Eosinophilia
por: Im, Soyoung, et al.
Publicado: (2022)

PB2044: TRIAL IN PROGRESS: OBSERVATIONAL STUDY IN PATIENTS WITH ADVANCED SYSTEMIC MASTOCYTOSIS TREATED IN ITALY WITH MIDOSTAURIN (OVIDIO)
por: Grifoni, F. I., et al.
Publicado: (2022)

Advances in the understanding and clinical management of mastocytosis and clonal mast cell activation syndromes
por: González-de-Olano, David, et al.
Publicado: (2016)

Childhood Cutaneous Mastocytosis: Revisited
por: Swarnkar, Bhavya, et al.
Publicado: (2023)

Cutaneous and Gastrointestinal Symptoms in Two Patients with Systemic Mastocytosis Successfully Treated with Omalizumab
por: Lieberoth, Sofie, et al.
Publicado: (2015)

Systemic mastocytosis, in the context of a deleterious germline SDHC variant, treated with ripretinib
por: Saheb Kashaf, Sara, et al.
Publicado: (2023)

Efficacy of Omalizumab in Indolent Systemic Mastocytosis
por: Slapnicar, Calum, et al.
Publicado: (2019)

Systemic mastocytosis – a diagnostic challenge
por: Lladó, Ana Cristina Amorim Oliveira Gaia, et al.
Publicado: (2014)

The Role of Avapritinib for the Treatment of Systemic Mastocytosis
por: Sumbly, Vikram, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_lgq8qq2manadds88shb2c7sj6a